natgillin/translations-raw huggingface dataset:
and R12, taken together with the nitrogen atom to which they are attached, form a 4- to 7-membered saturated ring optionally having an additional ring heteroatom selected from the group consisting of N, O and S and optionally substituted on any of the ring carbon atoms with 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of cyano, halo, hydroxy, amino, C3-6 heterocyclyl, C1-9 amide, C1-6 alkyl and C1-4 alkoxy, and further substituted on any additional ring nitrogen by hydrogen or a substituent selected from the group consisting of C3-8 cycloalkyl and C1-6 alkyl; and 
i C1-4 alkoksi; i pri čemu 4 do 7 člani zasićeni prsten je supstituiran na bilo kojem dodatnom dušiku u prstenu sa supstituentom odabranim iz skupine koju čine: vodik, C3-8 cikloalkil, i C1-6 alkil po izboru supstituiran s 1 do 7 supstituenata koji su neovisno odabrani iz skupine koju čine: C1-4 alkoksi; C1-9 amid; amino; C1-8alkilamino; C1-5 oksikarbonil; cijano; C3-8 cikloalkil; halo; hidroksi; i C3-6 heterociklil po izboru supstituiran na bilo kojem dušiku u prstenu C1-4 alkil; C1-10 heteroaril; i fenil po izboru supstituiran s 1 do 5 supstituenata koji su neovisno odabrani iz skupine koju čine C1-4 alkil, C1-4 alkoksi, C1-9 amid, amino, C1-8 alkilamino, C1-5 oksikarbonil, cijano, halo, hidroksil, nitro, C1-8 sulfonil, i trifluorometil; i
The spray dried powder was then added into a Pharmatec 5 Liter bin blender and then blended with microcrystalline cellulose and croscarmellose sodium over 10 minutes at 17 rpm. 
Sprej osušeni prašak se zatim doda u Pharmatec 5-litrenu miješalicu s posudom i zatim miješa s mikrokristalnom celulozom i kroskarameloza natrijem tijekom 10 minuta pri 17 okr/min.
When the user releases the pressure on actuation member 17, the valve element 5 returns to the intermediate position due to the biasing force of spring 15, but is limited in its movement from the intermediate position to the first position by a second stop 22 or second locking means. 
Kad korisnik prestane pritiskati element za pokretanje 17, element ventila 5 se vraća u međupoložaj zbog sile prenaprezanja opruge 15, ali je ograničen u svom pomaku od međupoložaja u prvi položaj zbog drugog graničnika 21 ili drugog sredstva za zabravljivanje.
The compound of any one of claims 1-15 wherein the viral infection is selected from the group consisting of: hepatitis B, hepatitis C, human immunodeficiency virus, Polio, Coxsackie A and B, Rhino, Echo, small pox, Ebola, and West Nile virus. 
Spoj prema bilo kojem od patentnih zahtjeva 1-15, naznačen time da se virusna infekcija bira iz skupine koja se sastoji od: hepatitis B, hepatitis C, humani virus imunodeficijencije, polio, Coxackie A i B, rino, echo, male boginje, ebola i virus West Nile.
A compound having Formula (V): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof, wherein: 
P (V) ili stereoizomer, tautomer, njegova farmaceutski prihvatljiva sol, gdje: prsten A je nezavisno odabran od
The composition of claim 10, wherein the loss in cognition disorder and/or neurodegeneration is selected from the group consisting of benign forgetfulness, mild cognitive impairment, dementia and Alzheimer's disorder. 
Pripravak za upotrebu prema zahtjevu 9, naznačen time da je gubitak kognitivnosti odabran iz skupine koja se sastoji od benigne zaboravnosti, blagog poremećaja kognitivnosti, demencije i Alzheimerove bolesti.
A solution of 4-bromomethyl-biphenyl (Intermediate 1, 3.00g, 12.2 mmol) in tetrahydrofuran (6 mL) was added dropwise over 10 minutes and the resulting solution stirred at 0 °C for 1.5 hours. 6 M Hydrochloric acid (15 mL) was added; then the crude reaction mixture was extracted with diethyl ether (3x50 mL). 
Otopinu 4-brommetilbifenila (Vleđuprodukt 1, 3,00 g, 12,2 mmol) u tetrahidrofuranu (6 ml) ukapava se 10 minuta, a dobivenu otopinu miješa 1,5 sati na 0 *C. Doda se 6 M klorovodična kiselina (15 ml), a sirovu reakcijsku smjesu ekstrahira dietileterom (3 X 50 ml).
The residue was purified by flash chromatography (SiO2) using 25 % ethyl acetate-hexanes. 
Ostatak se pročisti svjetlosnom kromatografijom (SiO2) uporabom 25% etil acetat-heksana.
In a second embodiment the pharmaceutical composition comprises a therapeutically effective amount of the active pharmaceutical ingredient in admixture with pharmaceutically acceptable excipients wherein the active pharmaceutical ingredient comprises about 5% to about 100% by weight of the crystalline monohydrate of the present invention. 
U drugoj implementaciji farmaceutski sastav sadržava terapijski djelotvornu količinu aktivnog farmaceutskog sastojka, u smjesi sa farmaceutski prihvatljivim ekscipijentma, gdje aktivni farmaceutski sastojak sadržava oko 10% do oko 100% težinski kristalnog monohidrata predmetnog izuma.
The infrastructure according to claim 14, in which energy transformation unit is mechanical or electromechanical, or is integrated electronically, and if the energy is intended to be accumulated, super-capacitors for charging accumulators are connected after the handwheel and the unit for transforming electricity, or a mechanism for accumulating potential energy to be later converted continuously is used to generate electricity with constant power. 
Infrastruktura u skladu s bilo kojim od patentnih zahtjeva 3 do 6, naznačena time što je jedinica za transformaciju energije (24) mehaničkog ili elektromehaničkog tipa, ili je integrirana elektroničkim putem, i ako se energija namjerava akumulirati, tj. pohraniti, superkondenzatori za punjenje akumulatora priključuju se nakon ručnog kotača i generatora električne energije (2), ili se mehanizam za akumuliranje potencijalne energije koja se kasnije neprekidno pretvara koristi za proizvodnju električne energije sa stalnom snagom.
The process of claim 12, further comprising lyophilizing the free or microencapsulated bacteria with lyoprotectants, wherein the lyoprotectants comprise 0.2 to 10% maltodextrin and 0.05 to 0.33% yeast extract, 0.05 to 2.5% inulin and 0.1 % yeast extract, or 0.3% inulin. 
Postupak iz patentnog zahtjeva 13, nadalje obuhvaća liofiliziranje slobodnih ili mikroenkapsuliranih bakterija s lioprotektantima, gdje lioprotektanti obuhvaćaju (a) 0.2 do 10% maltodekstrina 1 0.05 do 0.33% ekstrakta kvasca, (b) 0.05 do 2.5% inulina i 0.05 do 0.1% ekstrakta kvasca, ili (c) 0.3% inulina.
A process according to claim 11, wherein the reactions of steps a) and b) of the process according to claim 11 are both performed in toluene. 
Postupak prema zahtjevu 12 ili 13, naznačen time, da se obje reakcije iz koraka a) i b) iz postupka u skladu sa zahtjevom 12 ili 13, provode u toluenu.
The process of claim 1, wherein the ferric chloride is present in the reaction mixture in an amount in the range of from about 30 to about 1000 ppm. 
Postupak iz patentnog zahtjeva 1, pri čemu je željezov(IlI) klorid prisutan u reakcijskoj smjesi u količini koja je u rasponu od 30 do 1000 ppm.
The transactivative androgen agonistic activity of the compounds of the invention was measured in Chinese hamster ovary cells (CHO) transfected with the human androgen receptor (hAR), in combination with a mouse mammary tumor virus (MMTV), and luciferase receptor gene (incubation time 16 h, temperature 37°C) and compared with the activity of 5a-dihydrotestosterone [according to the procedure described by Schoonen, W.G.E.J. et al. Analyt. 
Aktivnost spojeva prema ovom izumu kao transaktivacijskih androgenih agonista mjerena je na stanicama jajnika kineskog hrčka (CHO), transficiranih ljudskim androgenim receptorom (hAR), u kombinaciji s virusom mišjeg tumora dojke (MMTV) i genom za luciferazni receptor (inkubacija 16 sati, temperatura 37 *C), te uspoređena s aktivnošću 5a-dihidrotestosterona [prema postupku opisanom u W.G.E_J. Schoonen i dr.: Analyt.
alkoxy; and —NR1aR2a; R1a is selected from the group consisting of: 
R'! je odabran iz grupe koja se sastoji od: a) b)
a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:362; 
slijed aminokiselina kodiran polinukleotidnim slijedom koji je najmanje 80% identičan slijedu SEQ ID NO:362; iii.
Y is optionally substituted C5-6 cycloalkyl, optionally substituted C5-6 cycloheteroalkyl, optionally substituted phenyl, or optionally substituted C5-6 heteroaryl; especially Y is cyclopentyl, cyclohexyl, thienyl, furyl, pyridinyl, or optionally substituted phenyl; more especially cyclohexyl or more especially phenyl, optionally substituted with 1 or 2 fluoro, chloro, methyl, hydroxy, methoxy, or trifluoromethyl groups; such as where the phenyl is unsubstituted, or is substituted and one of the substituents is in the 4-position, particularly where there is only one substituent; 
Y je po izboru supstituirani Cs.g cikloalkil, po izboru supstituirani C5.g cikloheteroalkil, po izboru supstituirani fenil ili po izboru supstituirani Csg heteroaril; posebno Y je ciklopentil, cikloheksil, tienil, furil, piridinil ili po izboru supstituirani fenil; prikladnije cikloheksil ili još prikladnije fenil, po izboru supstituiran sa 1 ili 2 floro, kloro, metil, hidroksi, metoksi ili triflorometil skupine; kao kad je fenil nesupstituiran, ili je supstituiran i jedan od supstituenata je u 4-poziciji, posebno kad je ondje samo jedan supstituent;
providing at least two sensors in a flexible and planar sensor envelope arranged on top of the mattress, said at least two sensors being adapted to measure a physical parameter which is relatable to a lying position used by a user; determining, based on input from said at least two sensors, a present lying position of a user, said lying position being determinable to be one of a set of at least two lying positions; 
omogućavanje barem jednog senzora, pri čemu su navedeni senzori prilagođeni za mjerenje fizičkog parametra koji se može prilagoditi ležećem položaju koji koristi korisnik, pri čemu su senzori smješteni u ovojnici senzora smještenoj na vrhu madraca, ovojnica senzora s karakteristikom električne impedancije koja varira s uobičajenom silom koja se vrši na nju;
In the chamber 27 of the guide 6 is housed a spring 30, operatively active on the cursor 7 to maintain it in an initial resting position. 
U komori 27 vodilice 6 je smještena opruga 30 koja prilikom rada djeluje na klizač 7 tako da ga održava u početnom položaju mirovanja.
The method of claim 1, wherein the first guide RNA comprises a first CRISPR RNA and a first tracrRNA fused together, and the second guide RNA comprises a second CRISPR RNA and a second tracrRNA fused together. 
prva vodilja RNA obuhvaća prvu CRISPR RNA i prvu tracrRNA fuzioniranu zajedno, i / ili drugu vodič RNA sadrži drugu CRISPR RNA i drugu tracrRNA spojenu zajedno;
In alternative embodiments, R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring. 
Ra je H ili alkil; ili R3 i Ra, zajedno sa atomima za koje su vezani, obrazuje 6-člani aril prsten ili 5-ili 6-člani heteroaril prsten;
A pharmaceutical formulation according to claim 1 or claim 2, wherein the concentration of polysorbate-80 is 0.03% (w/v). 
Farmaceutska formulacija u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što je koncentracija polisorbata-80 0,03% (tež./vol.).
a solid material, optionally grain, granulate, pellet, loose bait, chippings, block or tablet or dust, or a semi-solid material, the at least one other compartment (14, 24) being equipped with a further cover adapted to close the at least one other compartment (14, 24), wherein the further cover is an aroma-permeable cover. 
bar još jedan odjeljak (14, 24) koji sadrži mamac koji se sastoji od biocida koji sadrži rodenticidni materijal i koji mamac uključuje smjesu koja sadrži jedan ili više krutih materijala, po izboru zrna, granulata, kuglica, mamaca u rasutom stanju, krhotina, blokova ili tableta ili prašine, ili polukrutih materijala, bar još jedan odjeljak (14, 24) koji je opremljen s daljnjim poklopcem prilagođenim da zatvori bar još jedan odjeljak (14, 24), pri čemu daljnji poklopac propušta arome.
The IL-17 antagonist for use according to Claim 1, wherein the IL-17 antagonist is a monoclonal antibody or a monoclonal antibody fragment. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 1, naznačen time, da IL-17 antagonist je monoklonsko antitijelo ili fragment monoklonskog antitijela.
The process allows for the manufacture of ultra-high molecular weight polyolefin films of high quality. 
PATENTNI ZAHTJEVI Postupak proizvodnje filma od poliolefina ultra-visoke molekularne težine, a koji obuhvaća korake
A lip seal 47 is fitted on the internal surface of the line part 30 to guarantee a liquid-tight seal along the contact plane 36. 
Krajnja brtva 47 se nalazi na unutrašnjoj površini dijela cijevi 30 kojom se osigurava nepropusno brtvljenje uzduž dodirne ravnine 36.
The method of any one of items 1 to 39, wherein the fitted relations are fitted by an estimation chosen from least squares, ordinary least squares, linear, partial, total, generalized, weighted, non-linear, iteratively reweighted, ridge regression, least absolute deviations, Bayesian, Bayesian multivariate, reduced-rank, LASSO, elastic net estimator and combination thereof. 
Postupak u skladu s bilo kojim patentnim zahtjevom od 1 do 12, naznačen time, da se prilagođeni odnosi podešavaju procjenom odabranom od postupka najmanjih kvadrata, običnih najmanjih kvadrata, linearnog, djelomičnog, ukupnog, generaliziranog, ponderiranog, nelinearnog, iterativno re-ponderiranog, regresijom grebena, najmanjeg apsolutnog odstupanja, Bayesovog, Bayesov multivarijatnog, reduciranog ranga, LASSO, procjene elastične mreže i njihove kombinacije.
A method according to any preceding claim, wherein the binder is selected from phenol formaldehyde binder, urea formaldehyde binder, phenol urea formaldehyde binder, melamine formaldehyde binder, condensation resins, acrylates and other latex compositions, epoxy polymers, sodium silicate and hotmelts of polyurethane, polyethylene, polypropylene and polytetrafluoroethylene polymers. 
Metoda prema bilo kojem prethodnom zahtjevu, pri čemu se ljepilo odabire između sljedećih ljepila: fenol-formaldehidno ljepilo, karbamid-formaldehidno ljepilo, fenol-karbamid-formaldehidno ljepilo, melamin-formaldehidno ljepilo, kondenzacijska smola, akrilati i ostali lateksni spojevi, epoksidni polimeri, natrijevog silikat i topljeno ljepilo od poliuretana, polietana, polietilena, polipropilena i politetrafluoretilenskih polimera.
The door closer according to claim 2, wherein said at least one first and second planes are reciprocally parallel. 
Spojnica za zatvaranje vrata prema zahtjevu 1 ili 2, gdje su barem jedna prva i druga ravnina (1', m", 1 paralelne.
Method of removal of calcium from hydrocarbon feedstock, as claimed in claim 1, wherein said conventional process of separation is countercurrent extraction. 
Metoda uklanjanja kalcija iz ugljikovodične sirovine prema patentnom zahtjevu 1, naznačen time da je navedeni uobičajeni postupak razdvajanja protustrujna ekstrakcija.
Even more preferably, Ra and Ra′, equal or different each other, is a bromine atom, a hydroxy group; a C1-C3 alkoxy group; or an aromatic carbocyclic or heterocyclic ring, having 6 members, optionally substituted by one or two substituents selected from the group consisting of halogen, hydroxy, C1-C3 alkyl, C1-C3 alkoxy, —NR1R2 and —C(O)OH. 
Spojevi 1H-indazol-3-karboksamida prema zahtjevu 3, naznačeni time, da su svaki od R, i R, međusobno isti ili različiti, sljedeći: atom broma; hidroksi skupina; Ci-C3 alkoksi-skupina; ili nezasićeni karbociklički ili heterociklički prsten koji ima 6 članova, opcijski supstituiran s jednim ili dva supstituenta odabrana iz skupine koju čine halogen, hidroksi, C;-C> alkil, C,-Cs alkoksi, -NR;R2i -COOH; i
The composition for use according to claim 13, wherein the crenolanib or a salt thereof is administered orally, intravenously, or intraperitoneally. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol daju oralno, intravenozno ili intraperitonealno.
The process according to claim 9, wherein the working fluid flow enters the turbo-expander along an axial direction in a radially more internal zone of the turbo-expander and exits, expanded, along a radial or axial direction in a radially more external zone of the turbo-expander. 
Postupak sukladno prethodnom zahtjevu pri čemu tok radne tekućine ulazi u turbo ekspander (40) duž aksijalnog smjera u radijalno više internoj zoni turbo ekspandera (40) i izlazi, ekspandirana, duž aksijalnog smjera u radijalno više eksternoj zoni turbo ekspandera (40).
a microcontroller unit (104) that comprises pre-stored values such as digital sun exposure levels, temperature values, time limits between changes of the monitored sun exposure signal and a plurality of other variables, constants and database data and an algorithm-decision logic, 
- < mikrokontrolera (104) koji sadrži prethodno pohranjene vrijednosti kao što su digitalne razine izloženosti suncu, temperaturne vrijednosti, vremenske granice između izmjena promatranog signala izloženosti suncu i mnoštva drugih varijabli, konstanti i podataka u podatkovnoj bazi te algoritamske logike odlučivanja,
The base-addition salts of acidic compounds are prepared by standard procedures well known in the art. 
Bazične adicijske soli kiselih spojeva dobiva se standardnim postupcima, dobro pozatim u struci.
A compound according to any of claims 1 to 19 for use in a method of treating a disease or disorder that can be alleviated by inhibition of aldosterone synthase selected from diabetic nephropathy, glomerulosclerosis, glomerulonephritis, IGA nephropathy, nephritic syndrome, focal segmental glomerulosclerosis (FSGS), hypertension, pulmonary arterial hypertension, Conn's syndrome, systolic heart failure, diastolic heart failure, left ventricular dysfunction, left ventricular stiffness and fibrosis, left ventricular filling abnormalities, arterial stiffness, atherosclerosis and cardiovascular morbidity associated with primary or secondary hyperaldosteronism, adrenal hyperplasia and primary and secondary hyperaldosteronism. 
Spoj prema bilo kojem od zahtjeva 1 do 19, naznačen time, da se upotrebljava u postupku liječenja bolesti ili poremećaja koja/koji može biti ublažen/a putem inhibiranja sintaze aldosterona, te koja je odabrana/koji je odabran od sljedećih: dijabetska nefropatija, glomeruloskleroza, glomerulonefritis, IGA nefropatija, nefritički sindrom, fokalna segmentalna glomeruloskleroza (FSGS), hipertenzija, pulmonarna arterijska hipertenzija, Connov sindrom, sistolički zastoj srca, dijastolički zastoj srca, lijeva ventrikularna disfunkcija, lijeva ventrikularna ukočenost i fibroza, abnormalnosti kod lijevog ventrikularnog punjenja, ukočenost arterija, ateroskleroza 1 kardiovaskularni morbiditet povezan s primarnim i sekundarnim hiperaldosteronizmom, adrenalna hiperplazija i primarni i sekundarni hiperaldosteronizam.
A process for the preparation of a compound of Formula (I) according to claim 1, wherein G is hydrogen, which comprises cyclisation of the compound of the Formula (B) wherein R1, R2, R3, R4, R5, R6, R7, R8 and X have the meanings assigned to them in claim 1 and R is alkyl, under acidic or basic conditions. 
Postupak priprave spoja formule (I) prema zahtjevu 1, pri čemu G je vodik, naznačen time, da obuhvaća ciklizaciju spoja formule (B) gdje R', R', RR", R5, R5, R', Rši X imaju značenja koja su ima naznačena u zahtjevu 1, a R je alkil, pod kiselim uvjetima ili u bazičnim okolnostima.
A composition for use in improving at least one member selected from the group consisting of a social domain and a communication domain in a human having autism, wherein the composition includes a therapeutically effective amount at least one gamma-aminobutyric acid agonist. 
Pripravak namijenjen upotrebi u poboljšavanju najmanje jednog člana kojeg se bira iz skupine koju čine socijalne vještine i komunikacijske vještine kod osobe s autizmom, naznačen time što pripravak sadrži terapijski djelotvornu količinu najmanje jednog agonista Y-aminomaslačne kiseline.
The method according to claim 4 or 5, wherein the PEI and the plasmids are mixed before transfection according to a N/P ratio of less than 10, such as of around 6, wherein N/P refers to the number of nitrogen atoms in the PEI per oligonuclotide phosphate. 
Postupak u skladu s patentnim zahtjevom 4 ili 5, naznačen time što se PEI i plazmide pomiješa prije transficiranja prema omjeru N/P manjem od 10, poput otprilike 6, gdje se N/P odnosi na broj atoma dušika u PEI po oligonukleotid-fosfatu.
A dispenser according to any one of clauses 56 to 59, wherein the junction member comprises one or more slots, and the counter driver comprises one or more protrusions for engaging with the junction member so as to couple the junction member and counter driver. 
Dispenzer u skladu sa patentnim zahtjevom 28 ili 29, gdje element (41) za povezivane sadrži jedan ili više proreza (4504, 450b), 1 pokretač (206) brojača sadrži jedno ili više ispupčenja (222a, 222b) za angažiranje sa elementom za povezivanje da bi se upario element za povezivanje sa pokretačem brojača.
The closure 20 is held in place on vial 10 as shown by clamp part 30 which snap-fits over the flange 12. 
Zatvarač 20 se drži na svojem mjestu na bočici 10, kao što je prikazano, pomoću elementa za stezanje 30 koji je skočno zahvaćen preko prirubnice 12.
The reaction is performed at a temperature in the range, for example, 10 to 100°C, such as 70 to 90°C or, conveniently, at or near ambient temperature. 
Reakcija se provodi pri temperaturi u rasponu od, na primjer, 10 do 100 "C, primjerice 70 do 90 *C ili, poželjno, pri ili blizu temperature okoline.
a first component, being a composition for the preparation of a first colon cleansing solution comprising (or consisting essentially of): 
A) prvu komponentu koja je pripravak za pripremanje prve otopine za čišćenje debelog crijeva, te prva komponenta sadrži:
An apparatus for generating hydroxyl radicals according to claim 15, the base unit comprising a mixing chamber in fluid communication with an outlet of the reactant supply and an outlet of the ozone supply, the mixing chamber further comprising a dispensing outlet. 
Uređaj za stvaranje hidroksilnih radikala prema zahtjevu 8, osnovna jedinica (200) sadrži komoru za miješanje (228) u fluidnoj vezi s izlazom zalihe reaktanta i izlazom zalihe ozona, te komoru za miješanje (228) koja sadrži izlaz za doziranje.
Therap., 296:1051-1057, 2001), measuring the it dose (it=intratracheal administration) (in nmols/kg) which inhibited by 80% bronchial constriction for at least 210 min. 
Therap., 296:1051-1067,2001), mjerenjem IT doze (it=intratrahenalna administracija) (u nmol/kg) koja inhibira za 80% brahijalnu konstrikciju kroz najmanje 210 min.
advancing the plurality of cradles until the one or more plants encroach on an available growing space of another of the plants. The method of claim 1, wherein after the plants have reached the target growth, transferring the cradles to a subsequent growing machine for repeating the advancing the plurality of cradles along the path of the subsequent growing machine until the one or more plants have reached the target growth for the subsequent machine. 
Postupak prema zahtjevu 1 ili 2 naznačen time da, nakon što su biljke dostigle željeni rast, prebacivanje kolijevki za uzgoj (14) u naknadni stroj za uzgoj (10) radi ponavljanja napredovanja mnoštva kolijevki (14) duž staze (P) stroja za naknadni uzgoj sve dok jedna ili više biljaka ne dostignu ciljani rast za sljedeći stroj.
is C1-2-alkyl, wherein said C1-2-alkyl is substituted with —SO3H or —CO2H; or a pharmaceutically acceptable salt thereof. 
je C1-2-alkil, pri čemu spomenuti C1-2-alkil je supstituiran sa-SO3H ili -CO2H; ili njegova farmaceutski prihvatljiva sol, stereoizomer, mješavina stereoizomera, ili njegov tautomer.
The compound of claim 1 wherein R1 is H. 
Spoj prema patentnom zahtjevu 1 naznačen time što je Ry jednako H.